

To find the category this measure applies to (Medicare Stars, Federal Employee Program®, etc.), see our [chart of HEDIS® measures](#).

Osteoporosis Management in Women (OMW)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS®¹) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for osteoporosis management in women.

What is the measure?

The percentage of women age 67-85 who are on Medicare and who suffered a fracture and had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

- Notes:**
- Measurement year for OMW is a 12-month (1 year) window that begins with the identification of the initial fracture; this identification begins on July 1 of the year prior to the measurement year and ends on June 30 of the measurement year
 - Fractures of finger, toe, face and skull are not included in this measure

Exclusions

- Members who had a BMD test within 24 months prior to the fracture
- Members 12 months prior to the fracture who:
 - Had claims or encounter for osteoporosis therapy
 - Were dispensed prescription medication to treat osteoporosis
- Any of the following, any time during the measurement year:
 - Hospice care or using hospice services during the measurement year
 - palliative care anytime between July 1 of the year prior to the measurement year through the end of the measurement year
 - Members age 67 and older enrolled in an institutional special needs plan (I-SNP) or living long-term in an institution any time between July 1 of the year prior to the measurement year through the end of the measurement year
 - Members age 67-80 with frailty and advanced illness
 - Members age 81 and older with frailty

Service Needed for Compliance

One of the following testing or treatment for osteoporosis will meet criteria:

- A BMD test in any setting within a 180-day (6-month) period *after* the fracture
- Osteoporosis therapy within a 180-day (6-month) period *after* the fracture
- If the fracture resulted in an inpatient stay:
 - A BMD test during the inpatient stay
 - Long-acting osteoporosis therapy during the inpatient stay
- A dispensed prescription to treat osteoporosis within a 180-day (6-month) period after the fracture

(continued next page)

¹HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

All summaries of the measures contained herein are reproduced with permission from *HEDIS MY2022, Volume 2: Technical Specifications for Health Plans* by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Please see the final page of this document for the full copyright citation.

Osteoporosis Management in Women (OMW) *(continued)*

Osteoporosis Medication Therapy and Screening Test Codes

Osteoporosis Medication Therapy

HCPCS:

J0897 Injection, denosumab, 1 mg (J0897)

J1740 Injection, ibandronate sodium, 1 mg (J1740)

J3110 Injection, teriparatide, 10 mcg (J3110)

J3489 Injection, zoledronic acid, 1 mg (J3489)

J3111 Injection, romosozumab-aqqg, 1 mg (J3111)

Osteoporosis Screening Tests

CPT: 76977, 77078, 77080, 77081, 77085, 77806

Osteoporosis Medications

Description	Prescriptions
Bisphosphonates	Alendronate, alendronate-cholecalciferol, ibandronate, risedronate, zoledronic acid
Other agents	Abaloparatide, denosumab, raloxifene, romosozumab, teriparatide

Best Practices

- Order a BMD test on all women with a diagnosis of fracture
- Follow up with the member to ensure they had the test done; provide assistance with scheduling if needed
- When appropriate, prescribe medication to treat osteoporosis (bisphosphates)
- Encourage member to use their Florida Blue member card at the pharmacy
- Report the appropriate codes for the diagnosis and treatment provided and make sure that document in the medical record reflects all services billed
- Differentiate between active fractures and aftercare treatment

Content reproduced with permission from HEDIS® MY2022, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit ncqa.org/publications.